Olympus Duodenoscope Infection Lawsuit

A duodenoscope is a flexible endoscope used during endoscopic retrograde cholangiopancreatography, or ERCP, a medical procedure involving the bile ducts and pancreatic ducts.

During ERCP, medical professionals guide the scope through the mouth, stomach, and small intestine to reach the opening where these ducts drain, then use contrast dye and X-ray imaging to identify blockages, narrowing, stones, or other problems.

The device also has channels that let physicians pass tools through the scope to remove gallstones, place stents, take samples, or perform other treatment without open surgery.

Unlike simpler medical instruments used for routine upper endoscopy, a duodenoscope has a specialized elevator mechanism near the tip that helps control accessories during the procedure.

That same moving part is one reason duodenoscopes became central to infection concerns, because it creates tight spaces that are harder to fully clean and disinfect between patients.

FDA notes that duodenoscopes are used in more than 500,000 ERCP procedures each year in the United States.

ERCP with a duodenoscope is commonly used to:

• Treat blocked bile ducts: including obstruction caused by gallstones, scarring, or tumors.
• Remove bile duct stones: using small tools passed through the scope.
• Place or replace stents: to keep narrowed ducts open and restore drainage.
• Evaluate pancreatic and biliary disease: including strictures, leaks, and other duct problems.
• Perform minimally invasive treatment: by combining endoscopy with X-ray guidance instead of open surgery in many cases.

Why Duodenoscopes Have Been Linked to Infection Risk

Duodenoscopes have been linked to infection risk because the part of the device that makes ERCP possible also makes the device harder to fully reprocess between patients.

FDA says these scopes have complex designs with reusable hard-to-clean components, and studies of Olympus devices have focused on the elevator area near the tip, where fluids and debris can remain after use.

Standard sterilization and high-level disinfection depend on cleaning agents reaching every exposed surface, but the small recesses, moving parts, and enclosed spaces around the elevator can prevent that from happening consistently in real clinical settings.

Published research on duodenoscope contamination also describes biofilm formation inside channels and other difficult-to-clean areas, which can protect bacteria from detergents and disinfectants and leave ongoing contamination risks for later patients.

That is why patient infections have been reported even when medical providers followed the manufacturer’s instructions for cleaning and other proper procedures, and why FDA has said infections occur despite adherence to manufacturer cleaning protocols.

Many of those infections involved resistant organisms and became severe infections, including sepsis and cases requiring IV antibiotics, which makes them unlike ordinary bacterial infections seen after minor illness.

FDA continues to urge hospitals and medical device manufacturers to move toward partially or fully disposable duodenoscopes, stating that these designs may reduce between-patient contamination by half or more.

Federal scrutiny has also moved beyond cleaning instructions alone, with later Olympus enforcement actions citing quality system regulations alongside the older reprocessing concerns.

Duodenoscope-related infections can range from localized bacterial illness to systemic infection that spreads beyond the digestive tract.

The organisms most often discussed in this setting include drug resistant bacteria, especially CRE infections, as well as other gram-negative bacteria that can enter the bloodstream and become much harder to treat once symptoms escalate.

Patients may first develop fever, chills, abdominal pain, nausea, vomiting, weakness, or signs of infection in the days or weeks after ERCP, then progress to more serious complications if treatment is delayed.

In more severe cases, the infection can lead to bacteremia, sepsis, low blood pressure, breathing problems, and organ damage, which is why these cases are often described as life threatening infections.

The seriousness of these outcomes is one reason duodenoscope contamination became a major patient safety issue for hospitals, regulators, and manufacturers.

The sections below explain the main types of bacterial infections linked to duodenoscope exposure, the complications they can cause, and the symptoms patients may experience after an ERCP procedure.

Drug-Resistant Infections (CRE and Related Bacteria)

Drug-resistant duodenoscope infections usually involve bacteria introduced during ERCP when a contaminated scope comes into contact with a patient’s internal tissue or biliary system.

The organisms most closely tied to this issue are carbapenem-resistant Enterobacterales, commonly referred to as CRE infections, including resistant strains of Klebsiella pneumoniae and E. coli identified in outbreak investigations.

These infections became central to concerns involving gastrointestinal endoscopes because studies and FDA findings showed that some devices could remain contaminated after reprocessing, particularly around the elevator channel and distal tip.

Carbapenems are often used as last-line antibiotics for severe gram-negative infections, so resistance significantly limits available treatment options.

The broader infection profile also includes other drug resistant organisms found in healthcare settings, including vancomycin-resistant Enterococcus (VRE), although CRE remains the most consistently documented in duodenoscope transmission.

In bloodstream infections, CRE has been associated with mortality rates approaching 40% to 50%, particularly in vulnerable or hospitalized patients.

Drug-resistant infections linked to duodenoscope exposure can include:

• CRE (carbapenem-resistant Enterobacterales): a group of gram-negative bacteria resistant to carbapenem antibiotics, frequently identified in duodenoscope-related infection events.
• Carbapenem-resistant Klebsiella pneumoniae: a leading organism in documented duodenoscope outbreaks and a common cause of severe hospital-acquired infections.
• Carbapenem-resistant E. coli: another Enterobacterales organism that can develop carbapenem resistance and contribute to serious infection following exposure.
• Pseudomonas aeruginosa: a resistant gram-negative organism that can persist in moist environments and is often discussed in endoscope contamination studies.
• Vancomycin-resistant Enterococcus (VRE): a drug-resistant organism seen in healthcare-associated infections, included in broader discussions of contamination risks in reusable scopes.

These infections are defined by resistance patterns and the limited antibiotics available for treatment.

Transmission during ERCP allows bacteria to enter the biliary system or bloodstream, where resistant organisms are more difficult to eliminate.

The strongest documented link in duodenoscope cases remains CRE and related gram-negative bacteria identified in contamination and outbreak investigations.

Severe Complications Following Infection

Serious infections linked to duodenoscope exposure can progress quickly and affect multiple organ systems once bacteria enter the bloodstream.

Many cases involve sepsis, a systemic inflammatory response that can lead to rapid deterioration without immediate treatment.

These infections often require aggressive care, including hospitalization, IV antibiotics, and close monitoring due to the risk of complications.

In the most severe cases, infection can become fatal, particularly when drug-resistant bacteria are involved or treatment options are limited.

Severe complications following infection can include:

• Sepsis: a life-threatening response to infection that can cause widespread inflammation and tissue damage
• Septic shock: a severe form of sepsis involving dangerously low blood pressure and impaired blood flow to vital organs
• Organ failure: damage to the kidneys, liver, lungs, or heart resulting from infection or reduced oxygen delivery
• Acute respiratory distress syndrome (ARDS): a serious lung condition that limits oxygen exchange and may require mechanical ventilation
• Bloodstream infection (bacteremia): spread of bacteria throughout the body, increasing the risk of systemic illness
• Prolonged hospitalization: extended inpatient care due to infection severity and recovery complications
• Death: fatal outcomes reported in cases involving severe or drug-resistant infections

Symptoms and Onset After ERCP Procedures

Symptoms after ERCP procedures linked to infection do not always appear immediately and may develop over several days.

In many cases, patients begin to notice early signs of infection within 2 to 7 days after the procedure, although some infections can take longer to become clinically apparent.

The timing often depends on the type of bacteria involved and whether the infection remains localized or spreads into the bloodstream.

Infections involving resistant organisms or deeper tissue exposure may progress more quickly and require urgent medical attention.

Because ERCP involves direct access to the bile ducts and pancreas, infections can escalate faster than infections in less invasive procedures.

Symptoms following duodenoscope-related infection may include:

• Fever and chills
• Abdominal pain, especially in the upper abdomen
• Nausea and vomiting
• Jaundice (yellowing of the skin or eyes)
• Weakness or fatigue
• Rapid heart rate
• Low blood pressure
• Confusion or altered mental status
• Signs of sepsis, including difficulty breathing or decreased urine output

Olympus duodenoscope safety actions have centered on a small group of ERCP devices, especially older fixed-endcap models and later TJF models with updated reprocessing instructions.

The best-known Olympus duodenoscope in the federal record is the TJF-Q180V, which FDA cleared with design modifications intended to reduce bacterial infection risk after earlier contamination concerns.

Olympus later marketed the TJF Q190V as a newer-generation duodenoscope with a disposable distal cover, but postmarket review still led to updated reprocessing actions and recall-related notices.

In October 2025, Olympus issued an urgent field safety notice for certain TJF duodenoscopes after ongoing assessment of reprocessing identified concerns tied to positive bacterial cultures and infections.

Broader Olympus enforcement continued outside the duodenoscope line as well: in June 2025, the FDA issued import alerts affecting Olympus devices made at the Aizu facility in Japan after unresolved compliance problems, and FDA had already cited the site in a November 2022 warning letter for violations tied to quality system regulations.

Olympus duodenoscope models and related product lines identified in safety warnings, recalls, or major regulatory action include:

• TJF-Q180V duodenoscope: the Olympus model most closely associated with early FDA infection-risk actions and later design modifications.
• TJF-Q190V duodenoscope: a newer Olympus model with a disposable distal cover that was later subject to updated reprocessing guidance and recall-related action.
• TJF-Q190V, TJF-290V, and TJF-170V duodenovideoscopes: the TJF family named in the October 2025 urgent field safety notice updating reprocessing materials because of positive bacterial cultures and infections.
• JF-140F, PJF-160, TJF-160F, and TJF-160VF duodenoscopes: older Olympus ERCP models included in FDA’s earlier postmarket surveillance and infection-risk oversight.

The infection record tied to these devices has focused on whether complex elevator-channel geometry allowed bacteria and debris to remain after cleaning.

Public reporting and FDA materials describe contamination concerns even when hospitals followed Olympus reprocessing instructions, which is one reason duodenoscopes were linked to antibiotic resistant infections and other serious patient harm.

Olympus is a medical device company, but the duodenoscope history remains one of the clearest examples of how reusable device design can create persistent contamination risk in real clinical settings.

The 2025 import action did not target only duodenoscopes, but it extended scrutiny of Olympus Corporation and its subsidiaries by citing continuing compliance problems and what FDA described as unresolved manufacturing-system concerns, including ongoing failures to fully address prior issues.

Olympus scope lawsuits involve allegations that reusable duodenoscopes and related endoscopes transmitted “superbug” bacteria because key components could not be fully disinfected between patients.

Many of these legal claims were filed by patients and families who say they suffered severe infection, sepsis, prolonged hospitalization, or wrongful death after ERCP or other scope procedures.

The core allegations in Olympus litigation include defective design, failure to warn about contamination risks, inadequate cleaning instructions, manufacturing defects, and broader corporate misconduct tied to reporting and safety oversight.

Federal prosecutors also pursued a criminal case against Olympus in 2018, and the company agreed to pay $85 million after pleading guilty to failing to file required adverse-event reports involving duodenoscope infections and continuing to sell the devices in the United States despite those failures.

Olympus duodenoscope claims are not currently gathered into one nationwide federal MDL.

No single multidistrict litigation currently consolidates all federal cases involving Olympus duodenoscopes.

Olympus endoscope cases are being filed as individual lawsuits in state and federal courts across the United States.

Each case proceeds based on the specific facts of the procedure, the infection, and the medical records connecting the device to the injury.

You may be eligible to file an Olympus duodenoscope lawsuit if you underwent an ERCP or another qualifying scope procedure and later developed a serious infection tied to that treatment.

Cases are strongest when the infection required hospitalization and appeared within a medically significant timeframe after the procedure.

Sepsis, CRE, other superbug infections, and infection-related death are among the injuries most often reviewed in these claims.

Medical records, procedure reports, culture results, and hospitalization records are often central in medical device cases involving contaminated duodenoscopes.

These claims also turn on whether the facts support allegations of defective design, inadequate warnings, improper reprocessing instructions, or broader corporate negligence.

TorHoerman Law offers a confidential case evaluation to review whether the infection history, treatment timeline, and procedure details support a claim.

If the facts qualify, the firm can provide legal representation and help you pursue compensation for the harm caused by a contaminated Olympus duodenoscope.

Evidence in Duodenoscope Infection Cases

Evidence is central to proving that a duodenoscope was the source of infection and not another medical or environmental cause.

These cases often depend on detailed medical timelines that connect the procedure to the onset of infection within a defined period.

Documentation must also support the type of bacteria involved, the severity of the illness, and the treatment required.

In medical device cases, strong evidence allows attorneys to evaluate whether contamination, device design, or reprocessing failures may have contributed to the injury.

Evidence in duodenoscope infection cases may include:

• Procedure records identifying ERCP and the type of duodenoscope used
• Hospital admission records showing diagnosis and treatment of infection
• Laboratory results confirming bacterial infection (e.g., CRE, Klebsiella, E. coli)
• Timing records linking infection onset to the procedure
• Physician notes documenting complications such as sepsis or organ involvement
• Discharge summaries and follow-up care records
• Infection control reports or hospital exposure notifications
• Device tracking logs identifying specific equipment used during the procedure

Potential Compensation in Duodenoscope Infection Claims

Damages in duodenoscope infection cases refer to the measurable harm a patient experienced after exposure to a contaminated device.

In medical device litigation, attorneys assess damages by reviewing medical records, treatment history, and the long-term impact of the infection on a person’s health and ability to work.

This process includes evaluating both economic losses, such as medical costs and lost income, and non-economic harm, such as pain and physical suffering.

Lawyers use this information to calculate a claim that reflects the severity of the infection and advocate for compensation based on documented evidence and comparable cases.

Potential compensation in duodenoscope infection claims may include:

• Medical expenses, including hospitalization, ICU care, surgeries, and follow-up treatment
• Costs of prolonged antibiotic therapy and ongoing medical monitoring
• Lost wages and reduced earning capacity due to time away from work
• Pain and suffering related to infection and recovery
• Long-term or permanent disability caused by severe infection or organ damage
• Rehabilitation, home care, or assistive medical services
• Wrongful death damages for families who lost a loved one

Duodenoscope infection cases require a detailed review of medical records, procedure history, and the timing and severity of the infection to determine whether a contaminated device may have been involved.

TorHoerman Law has decades of experience handling mass tort cases and evaluates claims based on documented evidence, regulatory history, and the specific circumstances surrounding each procedure.

Our firm approaches these cases with a focus on accountability and a clear understanding of how these injuries develop in mass tort litigation.

If you or a family member suffered a serious infection after an ERCP or similar procedure, TorHoerman Law offers a no-obligation case evaluation to review your situation.

Contact us to discuss your medical history and determine whether you may have grounds to pursue a duodenoscope infection claim.